All News

In this interview, Stacy Loeb, MD (@LoebStacy), discusses why urologists should participate in Twitter, how it can benefit your daily practice, and some practical “dos and don’ts.”

Sexual function in men with lower urinary tract symptoms/BPH generally declines over time whether or not they are treated with medication. However, the magnitude of worsening differs depending on the treatment received, according to findings from the Medical Therapy of Prostatic Symptoms study.

Photoselective vaporization of the prostate is non-inferior to transurethral resection of the prostate in men with benign prostatic obstruction, researchers reported at the European Association of Urology annual congress in Stockholm, Sweden.

Use of surgery has increased steadily among all men with clinically localized prostate cancer, and in those with low-risk disease, brachytherapy utilization has declined.

As a number of common urologic surgeries have shifted from the inpatient to outpatient setting, potentially preventable deaths have increased following complications, the authors of a recently published study reported.

A significant number of older men with limited life expectancy continue to undergo routine prostate cancer screening, researchers say.

In this article, Robert A. Dowling, MD, discusses practical aspects of a work flow analysis in your office, including its relationship with health information technology and some helpful resources and tools.

The Centers for Medicare & Medicaid Services proposed changes to Medicare payment cover the Physician Quality Reporting System, value-based payment modification, potential relative value unit changes, targeted codes, and a change in global for future years, among other items.

A July 29 report by the Institute of Medicine on reforming the nation’s graduate medical education program has struck a nerve with the AUA and other medical societies by questioning the seriousness of continuing physician shortages in the United States.

The House of Delegates, the democratic policy-making body of the American Medical Association, meets twice a year to establish broad policy on health, medical, professional, and governance matters. As in previous years, several resolutions from this June’s meeting were of key interest to urologists.

The Androgen Study Group has called upon the Journal Oversight Committee to investigate what it deemed violations of “accepted standards of medical journal ethics and editorial integrity” by JAMA.

Data from 2 years of prospective follow-up in a multinational study show that the prostatic urethral lift (PUL [UroLift System, Neotract, Inc., Pleasanton, CA]) is a safe procedure that provides durable, clinically meaningful improvement of lower urinary tract symptoms due to BPH, reported Claus G. Roehrborn, MD, at the AUA annual meeting in Orlando, FL.

As health care providers, our prime directive is to help our patients. Unfortunately, this altruism does not exempt us from the possibility of a violent act by a patient against us or our staff.

Drugs and devices in the pipeline form Clarus Therapeutics, Nymox Pharmaceutical, Bioniche Life Sciences, Repros Therapeutics, BioLight Life Sciences Investments/Micromedic Technologies, Cubist Pharmaceuticals, Takeda Pharmaceutical, H. Lundbeck A/S, Transplant Genomics, Orion, Bayer, and Roche.

Recently published data from the European Randomised Study of Screening for Prostate Cancer (ERSPC) indicate that screening for prostate cancer could reduce deaths from the disease by about one-fifth.

Two independent published trials have validated the performance of an epigenetic test that could provide physicians with a better tool to help eliminate unnecessary repeat prostate biopsies.

The federal system for financing physician training and residency programs needs to be overhauled to ensure that the United States is producing the physicians that the nation needs, according to a new Institute of Medicine (IOM) report that the AUA says makes recommendations that would have a negative effect on teaching hospitals and fails to acknowledge a doctor shortage across all specialties.

This infographic depicts the efforts of several states to boost graduate medical education funding. Is your state among them?

To gain an endocrinologist’s perspective on current issues in testosterone therapy and hypogonadism, Urology Times interviewed Rebecca Z. Sokol MD, MPH, professor of obstetrics and gynecology and medicine at the Keck School of Medicine of the University of Southern California, Los Angeles.

All treatments entail some risk, including T therapy. At this point, there are no compelling data to support the notion that T therapy is associated with CV risks, and there is suggestive evidence it may even be helpful.

As policymakers learn about the burgeoning bottleneck between medical school graduation and graduate medical education, a number of novel approaches to physician training have launched from Sacramento to Jefferson City to Tallahassee. Not surprisingly, many of these solutions pit providers against one another amid concerns about patient safety and the dilution of professional standards.

The FDA has rejected Public Citizen’s petition to have a black box warning placed on the labels of testosterone-containing drugs available in the United States.

A genomic tool for prostate cancer appears to provide physicians and patients with improved decision making about the use of radiation therapy after radical prostatectomy.

A new study showing a survival benefit of more than 1 year with a chemotherapy-hormonal therapy combination given prior to castration resistance is being hailed by a leading prostate cancer expert as possibly representing a “new standard” in care.

Prospective, long-term follow-up in a large cohort of hypogonadal men treated with testosterone replacement therapy (TRT) provides no evidence that TRT increases the risk for prostate cancer.

This article reviews the evaluation and the medical and surgical management options for patients with what most experts refer to as chronic scrotal content pain.

Symptomatic hypogonadal men treated with clomiphene citrate (Clomid) or testosterone gels report similar satisfaction levels as age-matched men treated with testosterone injections, despite having significantly lower serum total testosterone levels, according to the findings of a recent retrospective study from Baylor College of Medicine, Houston.

Testosterone replacement therapy has been much debated in recent months, in light of two studies linking the treatment to increased risk of all-cause mortality, myocardial infarction, and stroke, prompting an FDA investigation into TRT’s safety and widespread criticism from members of the urologic community. In this article, Ajay Nehra, MD, discusses those studies, evolving attitudes toward “low T,” and the importance of individualizing treatment.